Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1172
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1172 (also known as V172) is an mRNA-based vaccine candidate developed for the prevention of respiratory syncytial virus (RSV) infection. It was originally part of a strategic collaboration between Moderna and Merck initiated in 2015. The vaccine utilizes Moderna's lipid nanoparticle (LNP) technology to deliver mRNA encoding a stabilized version of the RSV fusion (F) glycoprotein in its prefusion conformation (preF). Specifically, mRNA-1172 was designed as a next-generation version of mRNA-1777, incorporating a single-chain RSV F protein with interprotomer disulfides to enhance structural stability and improve the induction of neutralizing antibodies. In October 2020, Moderna regained all global rights to the program from Merck, which shifted its focus to RSV antibody programs. The candidate has been evaluated in Phase 1 clinical trials for both adult and pediatric populations, serving as a precursor to Moderna's later approved RSV vaccine, mRNA-1345 (mRESVIA).
- Other names
- RSV vaccine (mRNA)
02
Targets
RSV F (Respiratory syncytial virus fusion protein)
Beyond the preview
Go deeper on mRNA-1172.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1172.